Version 1
: Received: 3 September 2024 / Approved: 3 September 2024 / Online: 3 September 2024 (13:15:16 CEST)
How to cite:
Bodrova, V. V.; Shustova, O. N.; Golubeva, N. V.; Alieva, A. K.; Vlodzyanovsky, V. V.; Pevzner, D. V.; Mazurov, A. V. Platelet Function, Platelet Size and Content of Reticulated Platelets. Interactions in Patients Receiving Dual Antiplatelet Therapy. Preprints2024, 2024090248. https://doi.org/10.20944/preprints202409.0248.v1
Bodrova, V. V.; Shustova, O. N.; Golubeva, N. V.; Alieva, A. K.; Vlodzyanovsky, V. V.; Pevzner, D. V.; Mazurov, A. V. Platelet Function, Platelet Size and Content of Reticulated Platelets. Interactions in Patients Receiving Dual Antiplatelet Therapy. Preprints 2024, 2024090248. https://doi.org/10.20944/preprints202409.0248.v1
Bodrova, V. V.; Shustova, O. N.; Golubeva, N. V.; Alieva, A. K.; Vlodzyanovsky, V. V.; Pevzner, D. V.; Mazurov, A. V. Platelet Function, Platelet Size and Content of Reticulated Platelets. Interactions in Patients Receiving Dual Antiplatelet Therapy. Preprints2024, 2024090248. https://doi.org/10.20944/preprints202409.0248.v1
APA Style
Bodrova, V. V., Shustova, O. N., Golubeva, N. V., Alieva, A. K., Vlodzyanovsky, V. V., Pevzner, D. V., & Mazurov, A. V. (2024). Platelet Function, Platelet Size and Content of Reticulated Platelets. Interactions in Patients Receiving Dual Antiplatelet Therapy. Preprints. https://doi.org/10.20944/preprints202409.0248.v1
Chicago/Turabian Style
Bodrova, V. V., Dmitry V. Pevzner and Alexey V. Mazurov. 2024 "Platelet Function, Platelet Size and Content of Reticulated Platelets. Interactions in Patients Receiving Dual Antiplatelet Therapy" Preprints. https://doi.org/10.20944/preprints202409.0248.v1
Abstract
Increased platelet activity is a risk factor of thrombotic events in cardiovascular patients. We studied the relationship between platelet function, platelet size and content of reticulated platelets (RP) in patients with coronary heart disease (CHD, n = 55) and acute coronary syndrome (ACS, n = 95) receiving acetylsalicylic acid + clopidogrel or ticagrelor respectively. Control group consisted of patients with risk factors for CHD, but no CHD/ACS and free of antiplatelet drugs (n = 66). Platelet function was evaluated by exposure of activated glycoprotein (GP) IIb-IIIa and P-selectin. In the control group, platelets were activated by TRAP (Thrombin Receptor Activating Peptide) 10 µM, ADP 20, 5, 2.5 µM and in CHD/ACS groups, by TRAP 10 µM, ADP 20, 5 µM (+/- epinephrine 20 µM). Platelet size was assessed by mean volume, % large forms and forward scattering. RP were stained by thiazole orange. In the control group activated GP IIb-IIIa and P-selectin correlated with platelet size and RP content after platelet activation by all agonists. Despite the decrease of platelet activity by antiplatelet drugs, most correlations (primarily for activated GP IIb-IIIa) were preserved in CHD/ACS patients. In conclusion, increased platelet size and RP content are associated with increased platelet activity and reduced efficacy of antiplatelet therapy.
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
,
,
*
